Kenneth C. Frazier has moved between representing clients, leading a pharmaceutical company and widening access to employment. Raised in North Philadelphia, he earned a bachelor's degree from Pennsylvania State University and a law degree from Harvard, then made partner at Drinker Biddle & Reath. One of his cases stood apart from corporate work: the defense of a man on Alabama's death row.
Frazier worked with other lawyers on behalf of James Willie “Bo” Cochran. Their efforts helped overturn Cochran's conviction in 1995, and a retrial ended in acquittal in 1997. Public-interest work sat alongside the corporate career.
He joined Merck in 1992 and became its chief executive in 2011. The Franklin Institute identifies him as the first African American CEO of a major pharmaceutical company. His decisions covered research investment and the company's direction. After Vioxx was withdrawn in 2004, he directed Merck's defense in the litigation that followed. Merck's 2021 succession announcement credited his emphasis on research and the work of the company's scientific and management teams. Robert M. Davis succeeded him as chief executive in July 2021, and Frazier stayed on as executive chairman until 2022.
In August 2017, he resigned from the White House American Manufacturing Council after the violence in Charlottesville, explaining his opposition to intolerance and extremism.
Frazier also co-founded OneTen, a nonprofit whose mission, per his General Catalyst biography, is opening career opportunities for people without four-year degrees. At General Catalyst, he has advised on healthcare investments and partnerships. The Franklin Institute recognized his business leadership with its 2023 Bower Award.
